Severity
Low
FDA Drug recall · Reported October 14, 2020
Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot
VistaPharm, Inc. recalled NYSTATIN ORAL SUSPENSION, USP 100,000 units per mL Contains: Alcohol 0.5% v/v (Bubblegum … - a low-severity action.
NYSTATIN ORAL SUSPENSION, USP 100,000 units per mL Contains: Alcohol 0.5% v/v (Bubblegum … was recalled by VistaPharm, Inc. in October 14, 2020. Reason: Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot. Check the official notice for the remedy. Verify recall #D-0019-2021 with the FDA Drug before acting.
The recall
VistaPharm, Inc. issued this low-severity FDA Drug recall-Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot.
Sourced from official FDA Drug enforcement records. Verify recall #D-0019-2021 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0019-2021) was formally reported on October 14, 2020, with the manufacturer initiating the action on September 25, 2020. It is classified under Low severity (Class III), with a current status of Terminated. VistaPharm, Inc. is listed as the recalling firm, operating out of Largo, FL. Federal records list the affected scope as 14,244 16 oz bottles.
The documented reason for this recall is: Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot Distribution data in the federal record shows the product reached: Distributed Nationwide in the USA including Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
14,244 16 oz bottles
Related Recalls
6
5 from same agency
NYSTATIN ORAL SUSPENSION, USP 100,000 units per mL Contains: Alcohol 0.5% v/v (Bubblegum Flavored) 16 fl. oz. (480 mL) Manufactured by: VistaPharm, Inc. Largo FL 33771, USA NDC 66689-008-16 UPC 6668900816,
Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0019-2021 |
| Date reported | October 14, 2020 |
| Date initiated | September 25, 2020 |
| Recalling firm | VistaPharm, Inc. |
| Firm location | Largo, FL |
| Affected scope | 14,244 16 oz bottles |
| Distribution | Distributed Nationwide in the USA including Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported October 14, 2020. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.